These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
122 related articles for article (PubMed ID: 18771353)
1. What can be expected from nuclear medicine tomorrow? Barbet J; Kraeber-Bodéré F; Chatal JF Cancer Biother Radiopharm; 2008 Aug; 23(4):483-504. PubMed ID: 18771353 [TBL] [Abstract][Full Text] [Related]
2. Targeted therapy in nuclear medicine--current status and future prospects. Oyen WJ; Bodei L; Giammarile F; Maecke HR; Tennvall J; Luster M; Brans B Ann Oncol; 2007 Nov; 18(11):1782-92. PubMed ID: 17434893 [TBL] [Abstract][Full Text] [Related]
3. Nuclear medicine applications for neuroendocrine tumors. Chatal JF; Le Bodic MF; Kraeber-Bodéré F; Rousseau C; Resche I World J Surg; 2000 Nov; 24(11):1285-9. PubMed ID: 11038195 [TBL] [Abstract][Full Text] [Related]
7. 11th Meeting of the Berlin-Brandenburg Society of Nuclear Medicine, 29-30 October, 2004, Potsdam, Germany. Brockhuis B; Czepczyński R; Nucl Med Rev Cent East Eur; 2004; 7(2):195. PubMed ID: 15968615 [No Abstract] [Full Text] [Related]
8. Nuclear medicine in the treatment of neuroendocrine tumours--problems and perspectives. Grzela T; Bialoszewska A; Brawura-Biskupski-Samaha R Eur J Nucl Med Mol Imaging; 2007 Apr; 34(4):444-7. PubMed ID: 17136539 [No Abstract] [Full Text] [Related]
9. Recent advances in nuclear medicine in endocrine oncology. Luster M; Pfestroff A; Verburg FA Curr Opin Oncol; 2017 Jan; 29(1):1-6. PubMed ID: 27906859 [TBL] [Abstract][Full Text] [Related]
10. Is there life after technetium: what is the potential for developing new broad-based radionuclides? Srivastava SC Semin Nucl Med; 1996 Apr; 26(2):119-31. PubMed ID: 8723506 [TBL] [Abstract][Full Text] [Related]
11. Radiolabeled antibodies for cancer imaging and therapy. Barbet J; Bardiès M; Bourgeois M; Chatal JF; Chérel M; Davodeau F; Faivre-Chauvet A; Gestin JF; Kraeber-Bodéré F Methods Mol Biol; 2012; 907():681-97. PubMed ID: 22907380 [TBL] [Abstract][Full Text] [Related]
12. Molecular imaging and personalized medicine: an uncertain future. Nunn AD Cancer Biother Radiopharm; 2007 Dec; 22(6):722-39. PubMed ID: 18158763 [TBL] [Abstract][Full Text] [Related]
13. Advances in cancer therapy with radiolabeled monoclonal antibodies. Goldenberg DM; Sharkey RM Q J Nucl Med Mol Imaging; 2006 Dec; 50(4):248-64. PubMed ID: 17043623 [TBL] [Abstract][Full Text] [Related]
14. Therapeutic radionuclides in nuclear medicine: current and future prospects. Yeong CH; Cheng MH; Ng KH J Zhejiang Univ Sci B; 2014 Oct; 15(10):845-63. PubMed ID: 25294374 [TBL] [Abstract][Full Text] [Related]
15. [Radiolabeled antibodies for cancer treatment]. Barbet J; Chatal JF; Kraeber-Bodéré F Med Sci (Paris); 2009 Dec; 25(12):1039-45. PubMed ID: 20035676 [TBL] [Abstract][Full Text] [Related]
16. Clinical radionuclide therapy dosimetry: the quest for the "Holy Gray". Brans B; Bodei L; Giammarile F; Linden O; Luster M; Oyen WJG; Tennvall J Eur J Nucl Med Mol Imaging; 2007 May; 34(5):772-786. PubMed ID: 17268773 [TBL] [Abstract][Full Text] [Related]
17. New functional imaging modalities for chromaffin tumors, neuroblastomas and ganglioneuromas. Ilias I; Shulkin B; Pacak K Trends Endocrinol Metab; 2005 Mar; 16(2):66-72. PubMed ID: 15734147 [TBL] [Abstract][Full Text] [Related]
18. Veterinary nuclear medicine. Krzemiński M; Lass P; Teodorczyk J; Krajka J Nucl Med Rev Cent East Eur; 2004; 7(2):177-82. PubMed ID: 15968607 [No Abstract] [Full Text] [Related]